Search
Cytoskeleton disturbance in Alzheimer’s disease: a molecular and cellular study – MAALAD
The neuropathology of Alzheimer’s disease (AD) is characterized by both the accumulation of extracellular plaques containing Aß peptides, derived from ß-amyloid protein, and the formation of intra-neuronal fibrillary tangles composed of tau, a neuronal microtubule-associated protein. A key to unders
Interaction of the Tau and FKBP52 proteins; applications to Tauopathies. – TAF (Tau Association with FKBP52)
There is insufficient understanding and no efficient treatment to confront the dramatic increasing number of Alzheimer patients and other senile dementias. Intraneuronal tangles, mainly constituted of aggregated hyperphosphorylated Tau, are a biochemical hallmark of these neurodegenerative diseases
Tool use and dementia – DUO
Alzheimer's disease (AD) and related disorders cause cognitive changes that affect the behavior of the patient gradually limiting the activities and participation to the social life. This gradual loss of autonomy, has a close relationship with praxic disorders, especially tool use disorders, and que
Sleep, Cognition and Alzheimer – SCOAL
The objective is to study sleep disorders (changes in sleep architecture and/or appearance of sleep disorders) that occur early in mild cognitive impairment. - - 1. Sagaspe, P., Taillard, J., Chaufton, C., Berthomier, C., Brandewinder, M., Amiéva, H., Dartigues, J.F., Harston, S., Rainfray, M. & Phi
Peripheral inflammatory processes in Alzheimer disease: from biomarker profiling to pathophysiological studies; – CytokALZ
AD is the commonest cause of dementia in occidental countries and has become a major public health issue. Memory impairment is usually the earliest but also the core symptom of this disease. The diagnosis at a late stage is relatively easy but damageable for the handling of patients in terms of opti
Pathogenic mechanisms of frontotemporal dementia: Measuring Activity of Dendritic CHMP2B. – MAD CHMP2B
Frontotemporal Dementia (FTD) is the most prevailing type of dementia before age 64, and second only to Alzheimer's disease in older individuals. FTD is an extremely disabling, irreversible disease; the early age of onset (average 55+/-10 years) adds to the burden. FTD arises from degeneration of co
Cellular origins of metabolic deficits in Alzheimer's disease – MetAlz
A consensus is forming that the failure of numerous disease-modifying drugs in clinical trials for AD is likely attributable to patients being treated too late, when damage is irreversible. In this context, decreased brain metabolism visualized by using Positron Emission Tomography has been shown to
MMP-12 as an early marker and therapeutic target in Alzheimer’s disease progression – PREVENTAD
AD is generally viewed as a neurovascular disease, characterised essentially by the intracellular accumulation of neurofibrillary tangles, and the formation of amyloid plaques. Accumulation of Aß appears necessary, although perhaps not sufficient, to trigger neurodegeneration. Aß is generated from t